Is obesity a risk factor for vaccine non-responsiveness?

Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors...

Full description

Bibliographic Details
Main Authors: Katherine M Young, Clive M Gray, Linda-Gail Bekker
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3859613?pdf=render
id doaj-a0f507a22b504b0490888d852ad0f93e
record_format Article
spelling doaj-a0f507a22b504b0490888d852ad0f93e2020-11-24T21:56:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8277910.1371/journal.pone.0082779Is obesity a risk factor for vaccine non-responsiveness?Katherine M YoungClive M GrayLinda-Gail BekkerUnderstanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors of vaccine efficacy following recombinant hepatitis B (rHBV) vaccination in a cohort of HIV-uninfected, hepatitis B virus naïve women living in a peri-urban setting in Cape Town. Our aim was to define host biological risk factors associated with lack of vaccine uptake. We found a significant association (p=0.009) between body mass index (BMI) and lack of vaccine-specific IgG titre (<10 mIU/mL). Obese individuals (BMI ≥ 30 kg/m(2)) were significantly more likely to be non-responders following 2 rHBV vaccine doses (Adjusted Odds Ratio of 8.75; p=0.043). There was no observed association between vaccine responses and age, method of contraception or time from vaccination to antibody measurement. These data suggest that obesity-associated factors interfere with vaccine immunogenicity and possible efficacy.http://europepmc.org/articles/PMC3859613?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Katherine M Young
Clive M Gray
Linda-Gail Bekker
spellingShingle Katherine M Young
Clive M Gray
Linda-Gail Bekker
Is obesity a risk factor for vaccine non-responsiveness?
PLoS ONE
author_facet Katherine M Young
Clive M Gray
Linda-Gail Bekker
author_sort Katherine M Young
title Is obesity a risk factor for vaccine non-responsiveness?
title_short Is obesity a risk factor for vaccine non-responsiveness?
title_full Is obesity a risk factor for vaccine non-responsiveness?
title_fullStr Is obesity a risk factor for vaccine non-responsiveness?
title_full_unstemmed Is obesity a risk factor for vaccine non-responsiveness?
title_sort is obesity a risk factor for vaccine non-responsiveness?
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors of vaccine efficacy following recombinant hepatitis B (rHBV) vaccination in a cohort of HIV-uninfected, hepatitis B virus naïve women living in a peri-urban setting in Cape Town. Our aim was to define host biological risk factors associated with lack of vaccine uptake. We found a significant association (p=0.009) between body mass index (BMI) and lack of vaccine-specific IgG titre (<10 mIU/mL). Obese individuals (BMI ≥ 30 kg/m(2)) were significantly more likely to be non-responders following 2 rHBV vaccine doses (Adjusted Odds Ratio of 8.75; p=0.043). There was no observed association between vaccine responses and age, method of contraception or time from vaccination to antibody measurement. These data suggest that obesity-associated factors interfere with vaccine immunogenicity and possible efficacy.
url http://europepmc.org/articles/PMC3859613?pdf=render
work_keys_str_mv AT katherinemyoung isobesityariskfactorforvaccinenonresponsiveness
AT clivemgray isobesityariskfactorforvaccinenonresponsiveness
AT lindagailbekker isobesityariskfactorforvaccinenonresponsiveness
_version_ 1725857302083272704